drugset / Trial / NCT06508216
A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
Choice Of the Most Active Strategies for Short term recurring Triple Negative Breast Cancer: A phase Ib/II, open-label, modular, dose-finding and dose-expansion study to explore safety, tolerability, pharmacokinetics, and anti-tumor activity of novel therapeutics in patients with early relapsed metastatic triple-negative breast cancer
Timeline
- Start
- 2024-07-05
- Primary completion
- 2025-12-17
- Completion
- 2027-12-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Datopotamab deruxtecan | Monoclonal antibody | 6 mg/kg | — |
| Subject | Durvalumab | Monoclonal antibody | 1120 mg | — |